Keyword: Fred Hutchinson Cancer Research Center
A Fred Hutchison research team has found that targeting some ultra-conserved DNA segments could be a strategy for developing new cancer treatments.
As Bristol-Myers Squibb looked to subsume Big Biotech Celgene, its chief scientific officer Thomas Lynch decided to walk.
Lowering neutrophil levels in mouse models of non-small cell lung cancer improved responses to PD-1 inhibitors, a Fred Hutchinson team discovered.
The week’s news included a study of a Karyopharm drug in treating immunotherapy-resistant cancer and insight into how metformin promotes weight loss.
GlaxoSmithKline is joining forces with Lyell Immunopharma to boost the “fitness” of T cells treatments and improve their efficacy in solid tumors.
HighPassBio starts life with a phase 1 leukemia cell therapy and the support of a founder that raised $150 million to build a portfolio of startups.
The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.
Fred Hutch scientists used CRISPR-Cas9 to boost the production of fetal hemoglobin by targeting a specific population of stem cells.
Targeting DUX4 might improve the success of immunotherapies, scientists at Fred Hutchinson Cancer Research Center suggest.
A Fred Hutchinson team developed gold nanoparticles that can deliver CRISPR to mouse models of HIV and inherited blood disorders.
